Generex Biotechnology Corp. (fka GNBTQ)

[Solar_Express]

That is a great article Many positives re GNBT and subs

The NGIO/Generex Plan for Vaccine Development

Time is of the essence, and it appears to me that Generex is a very good bet for a first line preventive vaccine for coronavirus. I say a “first line” vaccine because these vaccines may supercharge the body’s immune system making the likihood of death much smaller, but according to Eric von Hofe, patients may still suffer, the point is that likihood of death drops. So perhaps work needs to continue for regular type vaccines, but in the current situation, a pandemic, we need something as soon as we can get it. And a typical vaccine will take probably take a year or more. I think just about everyone would want a “first line” vaccine, or synthetic vaccine, as soon as they could get it.

These are people waiting to show they have the stuff. They are extremely well-motivated. Moscato wants to show that his leadership can lead to products. Same for Eric von Hofe, of NGIO, who has already developed vaccines for avian flu, swine flu, SARS (a coronavirus), but they came too late, and he would like to show his technology can be useful in this kind of situation. Same goes for Anna De Groot of Epivax, who was connected to Generex through NGIO director, Carol Nacy, though it is not entirely a new connection, NGIO’s Eric von Hofe said, “we have known Dr. De Groot and her excellent work on vaccines and the immune system for over 20 years.”

Epivax has the computational tools NGIO needs to nail down some epitope targets. “As soon as the [DNA] sequence was published, I said, ‘could we please analyze this sequence for potential vaccine design?’” says Annie De Groot, an immunologist and co-founder of Rhode Island-based EpiVax. “Three hours later, we had the essential elements for designing a vaccine.” Her desired time frame is a month: You could get into a phase one safety trial within weeks,” De Groot says. “Four weeks at the shortest,” from start to finish.

Generex outlined their strategy in a recent press release. NGIO will use De Groot’s predictions about epitopes to synthesize amino acid strings (peptides) that will be sent to China to test how they respond in the blood of those who have survived the infection, who will have immune cells that have learned how to respond to the infection. They will then see which peptides the immune cells and antibodies are responding to, and that will tell them which hybrid Ii-key peptides they need to trigger the immune system. Then you have the basis for your vaccine.

For the dreamers: Generex’s S-1 suggests a fee of $2 per person. If China has 1.4 billion people, that multiplies out to $2.8 billion. Probably it will take far less to stop the virus, but it could still be in the hundreds of millions.

Though I have contradictory opinions to sort out. De Groot says that manufacture of these vaccines is difficult and expensive, and will be used to protect medical professionals, but von Hofe told me they were not expensive, and I presume they could be used by vast segments of the population. I sent a query to CEO Moscato, who wrote, “Synthetic peptides against the traditional peptides are far far less expensive.”

In any event, medical professionals will get the vaccine first, and perhaps a learning curve will bring down the cost, so that it will be feasible to vaccinate large swaths of the population.

The race is on. Inovio (INO) has said it will begin human trials in April. Moderna (MRNA) is also in the contest, working on an RNA vaccine, which may take longer. But given the relative market caps shown below, I would take it that the market doesn’t even know NGIO (OTCQB:GNBT) is in the race.

https://seekingalpha.com/article/4330919-basket-of-biotechs?utm_medium=email&utm_source=seeking_alpha&mail_subject=cydy-gnbt-a-basket-of-biotechs&utm_campaign=rta-stock-article&utm_content=link-0